title: Mechanisms of blood pressure alterations in response to the Valsalva maneuver in postural tachycardia syndrome.
abstract: The postural tachycardia syndrome (POTS) is characterized clinically by orthostatic lightheadedness and tachycardia. When these patients perform a Valsalva maneuver, there is an excessive blood pressure increment after cessation of the maneuver (phase IV) that is sometimes associated with headaches. It is not known whether excessive phase IV is due to excessive peripheral vascular tone (an alpha-adrenergic mechanism) or is a manifestation of increased beta-adrenergic tone (hyperadrenergic state). The authors undertook a pharmacologic study evaluating the effect of intravenous phentolamine (alpha-adrenergic antagonist) and propranolol (beta-adrenergic antagonist) on the different phases of the Valsalva maneuver in a group of patients with POTS and age-matched normal control subjects. Patients with POTS had mean phases, when compared with controls, that were characterized by more negative II_E (p = 0.07), smaller II_L (p = 0.04), and significantly larger phase IV (p = 0.001). The effect of phentolamine was qualitatively and quantitatively different in POTS when compared with controls. Ten mg phentolamine in controls resulted in a significant accentuation of phase II_E (p = 0.001), attenuation of phase II_L (p = 0.002), and increase of phase IV (57.6 vs 30.7 mm Hg; p = 0.025). These changes resembled those of patients with POTS at baseline. In patients with POTS, the phase II abnormalities, already present, were further accentuated (p <0.001), and phase IV became smaller (50.6 vs 73.8 mm Hg; p = 0.09). Propranolol had no significant effect on phases II_E and II_L, but significantly reduced phase IV in both controls (p <0.05) and in patients with POTS (p <0.001) and improved the headache symptoms, when present, during and after phase IV. The authors conclude that phase IV is mainly under beta-adrenergic regulation and that the exaggerated phase IV in POTS is a result of a hyperadrenergic state.
authors.affiliation: Department of Neurology, Mayo Clinic, Rochester, Minnesota 55905, USA.
authors.forename: P
authors.initials: P
authors.lastname: Sandroni
authors.forename: V
authors.initials: V
authors.lastname: Novak
authors.forename: T L
authors.initials: TL
authors.lastname: Opfer-Gehrking
authors.forename: C A
authors.initials: CA
authors.lastname: Huck
authors.forename: P A
authors.initials: PA
authors.lastname: Low
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology*; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000328:Adult; D001794:Blood Pressure; D002319:Cardiovascular System / Q000503:physiopathology; D005260:Female; D005483:Flushing / Q000139:chemically induced; D006801:Humans; D010646:Phentolamine / Q000494:pharmacology; D011187:Posture / Q000502:physiology*; D011433:Propranolol / Q000494:pharmacology; D012016:Reference Values; D013577:Syndrome; D013610:Tachycardia / Q000209:etiology* / Q000503:physiopathology*; D014636:Valsalva Maneuver / Q000187:drug effects
chemical_list: D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D011433:Propranolol; D010646:Phentolamine